OAB & Urgency Urinary Incontinence
Overactive bladder (OAB) and urgency urinary incontinence (UUI) are managed across a menu of treatment categories rather than a strict stepwise ladder.[5] The AUA/SUFU 2024 guideline permits minimally invasive treatment without mandatory prior behavioral or drug trials through shared decision-making; this is an Expert Opinion option.[5]
Decision Framework
The guideline describes incontinence management, behavioral therapy, optimization of comorbidities, noninvasive therapy, pharmacologic therapy, minimally invasive therapy, invasive therapy and indwelling catheters. Discuss absorbent products, other containment options and barrier creams with all patients who have UUI .[5] Bladder training is offered to all patients with OAB , as are behavioral therapies .[5] β3-agonists or antimuscarinics are oral options, with side-effect and cognitive-risk counseling. SNM, tibial nerve stimulation and intradetrusor botulinum toxin should be offered after inadequate response or intolerance to behavioral or drug therapy ; earlier procedural access without those trials is separately permitted through shared decision-making . Augmentation or diversion is reserved for severely impacted patients after other options fail. Minimum initial office evaluation is symptom-focused history, physical examination and urinalysis; PVR, questionnaires and a voiding diary are selective aids, not universal requirements. Urodynamics, cystoscopy and imaging are not routine initial tests. See guideline statements 1–6 and 23–31.
The EAU 2026 non-neurogenic female LUTS guideline is more stepwise. It recommends bladder training first-line ; anticholinergics (extended-release preferred) or β3 agonists for women who fail conservative management , with early review ; onabotulinumtoxinA 100 U for OAB/UUI refractory to conservative or drug treatment ; SNM for UUI refractory to anticholinergic therapy ; and PTNS as an option . It advises caution with long-term anticholinergics in older women, particularly with cognitive risk, and assessing anticholinergic burden (both Strong); it reports that oxybutynin may worsen cognition in older women (level 2) and darifenacin, fesoterodine, solifenacin and trospium as not shown to do so in short-term studies (level 1b).[16] Vaginal laser is not offered for OAB outside research ; augmentation cystoplasty is offered only after all other options fail , with lifelong follow-up.
Treatment Selection by Clinical Scenario
| Clinical Scenario | Possible choice | Alternative(s) | Key Considerations |
|---|---|---|---|
| Mild OAB, prefers non-pharmacologic | Behavioral therapy + PFMT ± TTNS | Bladder training alone | Adherence-dependent; few adverse effects with behavioral and noninvasive therapies per the AUA/SUFU 2024 guideline |
| OAB / UUI, initial pharmacotherapy | β-3 agonist (vibegron or mirabegron) | Antimuscarinic | A β3-agonist trial is typically preferred before an antimuscarinic when cognitive risk matters; choose by patient factors. Use antimuscarinics with extreme caution in narrow-angle glaucoma, impaired gastric emptying, or a history of urinary retention .[5] US-labeled vibegron dose is 75 mg once daily, not 100 mg. See the current US prescribing information. |
| Inadequate response to oral monotherapy | Combine a β3 agonist and an antimuscarinic (mirabegron 50 mg plus solifenacin 5 mg studied) | Switch drug or class | AUA/SUFU permits different-class combination .[5] SYNERGY II randomized wet-OAB patients to combination or either monotherapy for 12 months (treatment-emergent adverse events: 49% combination, 41% mirabegron, 44% solifenacin).[1] BESIDE added mirabegron after inadequate response to solifenacin 5 mg; combination beat solifenacin 5 mg and was noninferior to 10 mg on key secondary endpoints, with superiority over 10 mg for daily micturitions.[2] The panel generalized the class-combination principle. Monitor anticholinergic burden. |
| Older adult or cognitive concerns | β-3 agonist often preferred | If an antimuscarinic is chosen, consider lower-CNS-penetration agents such as trospium, while counseling about anticholinergic exposure and monitoring cognition | Trospium poorly crosses the blood-brain barrier; observational drug-specific rankings conflict. The Malcher 2022 class-exposure aOR was 1.48 at >365 defined daily doses.[3] |
| Patient prefers to avoid daily medication | Intradetrusor onabotulinumtoxinA 100 U or SNM or iTNM | PTNS | May be offered without mandatory earlier therapy after counseling; this is the guideline's Expert Opinion early-access option.[5] PTNS has been studied in treatment-naive patients in a single-arm study and in a randomized comparison with tolterodine.[5][9] US labels differ: BOTOX for OAB requires prior anticholinergic inadequate response or intolerance; eCoin requires inadequate response or intolerance to conservative treatment or a successful PTNS trial; Altaviva requires failure or intolerance of conservative treatment. Revi has no mandatory prior-treatment-failure condition, but its FDA summary contraindicates use in men with BPH or other lower urinary tract obstruction and in pregnancy. |
| Inadequate response or intolerance | BTX 100 U or SNM or tibial nerve stimulation, including an implantable option in selected patients | iTNM or office PTNS according to device eligibility and treatment burden | AUA's Moderate Recommendation (Grade A evidence) is to offer the treatment families after inadequate response/intolerance.[5] |
| Refractory to BTX and neuromodulation | Augmentation cystoplasty | — | Last surgical resort; assess willingness and ability for CIC given the high postoperative risk, and plan lifelong surveillance (EAU 2026 female LUTS, Strong). |
| Severely impacted OAB after all other therapies fail | Urinary diversion | Chronic indwelling catheter only when OAB therapies are contraindicated, ineffective or no longer desired | Diversion has major surgical morbidity; chronic catheterization requires separate harm counseling.[5] |
| Male with OAB + BPH | Vibegron 75 mg[15] added to ongoing BPH pharmacotherapy when using its specific US BPH indication | Mirabegron | The GEMTESA US label specifies men on BPH drug therapy; Study 3005 used an alpha-blocker with or without a 5-alpha-reductase inhibitor. AUA/SUFU Statement 33[5] separately permits β3-agonist monotherapy. |
Minimally-Invasive Sub-Comparison
When pharmacotherapy fails or is declined, the choice among BTX, SNM, iTNM, and PTNS involves distinct trade-offs.
| Feature | Intradetrusor BTX 100 U | Sacral Neuromodulation (SNM) | Implantable TNS (iTNM) | PTNS |
|---|---|---|---|---|
| Reported response | Improves UUI in trials of 100 U | ≥50% UUI-episode response 71.8% (weighted single-arm average among permanently implanted SNM patients; trial-phase nonresponders were excluded where tested, Amundsen 2025[10]); 5-year composite OAB therapeutic success was 67% (modified completers) or 82% (completers) in Siegel 2018[11]; 272 of 340 test-phase completers were implanted, and success included UUI or urgency-frequency response or normalization to fewer than eight voids/day | ≥50% UUI-episode response 71.3% (weighted single-arm average, Amundsen 2025[10]; OAB-symptom response 79.4% vs 73.9% for SNM); 79% of 97 women assessed at 24 months after 151 implants in the single-arm pivotal OASIS Revi study (≥50% fewer UUI episodes on a 3-day diary; Heesakkers 2025[12]) | 68% pooled success in Wang 2020[13] meta-analysis |
| Duration | Repeat injections typically every 3–12 mo (AUA/SUFU); often ~6–9 mo | Continuous; generator life varies by model and settings (Axonics R20 is rated for at least 20 years)[6] | Scheduled, device-specific stimulation: eCoin (FDA Model UUI manual) has a nonrechargeable implant; Revi (FDA DEN220073) uses an externally powered, battery-free implant; Altaviva (FDA Model P7850N guide) has a rechargeable implant | Ongoing maintenance sessions |
| Reversibility | Wears off | Device removal | Device removal | Fully reversible |
| Trial phase needed | No | Yes (PNE / staged implant) | No | No |
| Key risks | UTI and retention; 6.5% initiated CIC versus 0.4% placebo in pooled US-label OAB trials[4]; catheterization planning is required | Implant-site pain, lead issues and revision/removal risk | Device-specific implant and follow-up risks | Usually low procedural burden, but repeated visits |
| Office burden | Repeat injections, typically every 3–12 mo | Low after implant | Low (home-based) | High — weekly + maintenance |
| MRI compatibility | N/A | Verify model-specific MRI conditions | eCoin: the implanted lower leg must remain outside the scanner and the device at least 20 cm from the bore edge under FDA Model UUI labeling[14]; verify separate Revi and Altaviva conditions | N/A |
The BOTOX US label specifies 100 U as the recommended and maximum adult OAB intradetrusor dose and reports CIC initiation after 100-U treatment in 36/552 (6.5%) versus 2/542 (0.4%) with placebo (Table 10).[4] Among patients who initiated CIC for urinary retention after BOTOX 100 U in the label trials (36/552), median catheterization lasted 63 days.[4] Measure baseline PVR before injection.[5] Intradetrusor BOTOX is contraindicated in patients with UTI or with urinary retention or PVR >200 mL who do not routinely perform CIC; treat only patients willing and able to initiate catheterization if needed.[4] The guideline advises caution with a baseline PVR above the BTX trial exclusion thresholds, which varied from 100 to 200 mL, and calls for PVR measurement if symptoms fail to improve or worsen.[5] The US label directs PVR assessment within two weeks for patients not already catheterizing and periodically as medically appropriate through 12 weeks.
The 2024 AUA/SUFU guideline recommends offering percutaneous tibial nerve stimulation but makes no recommendation specific to implantable tibial stimulators; the eCoin and Revi pivotal efficacy studies were single-arm. In a sham-controlled Intibia trial of adults with UUI, 86/137 active participants (62.8%) versus 28/67 sham participants (41.8%) exceeded the OABq-SF symptom-bother minimum clinically important difference at three months (p = 0.0046); the primary UUI-episode responder analysis was reserved for a separate report.[7]
Antimuscarinic Cognitive-Risk Considerations
In the Malcher 2022 case-control study, greater combined OAB-anticholinergic exposure was associated with dementia (aOR 1.07 at 1–90 defined daily doses, 1.29 at 91–365, and 1.48 at >365).[3] In Danish registry data, anticholinergic bladder drug use was associated with more dementia diagnoses than nonuse (IRR 1.44, 95% CI 1.40–1.48), but fewer than mirabegron use in a separate new-user comparison (IRR 0.82, 95% CI 0.74–0.92); residual confounding remains possible.[8] The AUA/SUFU guideline recommends discussing possible cognitive risk with patients taking or prescribed antimuscarinics.[5] The pharmacology hub holds agent-specific details.
| Consideration | Agents | Notes |
|---|---|---|
| Lower expected CNS penetration, not proven dementia-safe | Trospium (quaternary amine); Fesoterodine | Trospium poorly crosses the BBB; the guideline names fesoterodine, darifenacin and trospium as theoretically lower-risk on permeability grounds; observational dementia signals differ across cohorts. |
| Other agent-specific evidence | Darifenacin, tolterodine ER, solifenacin | CNS penetration, short-term cognitive outcomes and observational dementia associations differ. |
| Greater concern | Oxybutynin, especially chronic oral use | Higher CNS penetration and observational dementia signals warrant particular caution. |
Stepwise Escalation (Optional / When Patient Prefers a Graduated Approach)
The 2024 guideline eliminates mandatory step therapy, but many patients still prefer a graduated approach:
- Behavioral therapies: bladder training, fluid, caffeine and alcohol modification, urgency suppression, weight loss
- Non-invasive therapies: PFMT ± biofeedback, TTNS, transvaginal electrical stimulation
- Pharmacotherapy: choose a β3 agonist or antimuscarinic by adverse-effect profile and preference; after inadequate response, switch medication within or between classes, or combine different classes.[5]
- Minimally invasive: BTX 100 U[4], SNM, iTNM, or PTNS
- Augmentation cystoplasty
- Urinary diversion or indwelling catheter
| Treatment | Category | Best for / indication |
|---|---|---|
| Behavioral Therapy (Bladder Training + Urgency Suppression) | Behavioral | Offer bladder training to all patients with OAB <Rec>(AUA/SUFU 2024 Strong Recommendation, Grade A)</Rec> and behavioral therapies to all patients with OAB <Rec>(Clinical Principle)</Rec>. |
| Fluid Management & Dietary Modifications | Behavioral | Offer fluid-timing review and a diary-guided, time-limited trial of suspected triggers (caffeine, alcohol, carbonation, artificial sweeteners), with rechallenge rather than blanket avoidance. |
| Weight Loss | Behavioral | BMI ≥ 25 — modest UUI benefit (smaller effect than SUI). |
| Pelvic Floor Muscle Training (PFMT) | Non-Invasive | Hypotonic phenotype — strengthening; hypertonic — down-training. Do not equate with Kegels for guarded floors. |
| Transcutaneous Tibial Nerve Stimulation (TTNS) | Non-Invasive | Selected patients with OAB, with or without UUI, seeking noninvasive surface-electrode tibial stimulation; protocols and response vary. |
| Pelvic Floor Electrical Stimulation | Non-Invasive | Patients who cannot voluntarily contract the pelvic floor; adjunct to PFMT. |
| Beta-3 Agonists (Vibegron / Mirabegron) | Pharmacological | Oral treatment option; often preferred when anticholinergic cognitive risk matters. Check agent-specific labeling and retention risk. |
| Antimuscarinics | Pharmacological | Oral treatment option chosen through shared decision-making; discuss possible cognitive risk, especially with chronic exposure. |
| Combination β-3 + Antimuscarinic | Pharmacological | Inadequate response to monotherapy; mirabegron 50 + solifenacin 5 most studied. |
| Intradetrusor OnabotulinumtoxinA (100 U) | Minimally Invasive | OAB / UUI when injection burden and retention/UTI risks are acceptable; ensure a catheterization plan. |
| Sacral Neuromodulation (SNM) | Minimally Invasive | Refractory OAB / UUI; non-obstructive retention; trial phase to predict response. |
| Implantable Tibial Nerve Stimulation (eCoin / Revi / Altaviva) | Minimally Invasive | Selected patients with urgency urinary incontinence seeking implantable tibial stimulation; device-specific indications, contraindications, efficacy and follow-up apply. |
| Percutaneous Tibial Nerve Stimulation (PTNS) | Minimally Invasive | Refractory OAB; patients accepting weekly office visits and ongoing maintenance. |
| Augmentation Cystoplasty (Enterocystoplasty) | Invasive Surgical | Severely impacted patient refractory to all third-line therapies; CIC-tolerant. |
| Urinary Diversion | Invasive Surgical | Last-resort surgical option for intractable incontinence with non-functional bladder. |
| Indwelling Catheter (Urethral or Suprapubic) | Indwelling Catheter | Only when OAB treatments are contraindicated, ineffective, or no longer desired; counsel on chronic-catheter harm and consider suprapubic drainage to reduce urethral injury. |
Videos
References
1. Gratzke C, et al. "Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II)." Eur Urol. 2018;74(4):501-509. doi:10.1016/j.eururo.2018.05.005
2. Drake MJ, et al. "Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)." Eur Urol. 2016;70(1):136-145. doi:10.1016/j.eururo.2016.02.030
3. Malcher MF, et al. "Dementia Associated with Anticholinergic Drugs Used for Overactive Bladder: A Nested Case-Control Study Using the French National Medical-Administrative Database." J Urol. 2022;208(4):863-871. doi:10.1097/JU.0000000000002804
4. AbbVie. "BOTOX (onabotulinumtoxinA) US Prescribing Information." Revised October 2024, Table 10, Overactive Bladder. US label
5. Cameron AP, Chung DE, Dielubanza EJ, et al. "The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder." Neurourol Urodyn. 2024;43(8):1742-1752. doi:10.1002/nau.25532
6. Axonics, Inc. "Therapy Guide: Living with Axonics Therapy for Bladder or Bowel Control." December 2025, p.6. Manufacturer guide
7. Mangel J, Miller K, Erickson T, Dieter A, Roovers JP, Matthews CA. "Randomized, sham-controlled, double-blind trial of the Intibia System in urge urinary incontinence: quality-of-life outcomes." Int Urogynecol J. 2026. doi:10.1007/s00192-026-06636-1
8. Pourhadi N, Janbek J, Gasse C, et al. "Bladder drugs and risk of dementia: Danish nationwide active comparator study." BMJ Med. 2025;4(1):e001125. doi:10.1136/bmjmed-2024-001125
9. Preyer O, et al. "Percutaneous tibial nerve stimulation versus tolterodine for overactive bladder in women: a randomised controlled trial." Eur J Obstet Gynecol Reprod Biol. 2015;191:51-56. doi:10.1016/j.ejogrb.2015.05.014
10. Amundsen CL, et al. "Sacral and Implantable Tibial Neuromodulation for the Management of Overactive Bladder: A Systematic Review and Meta-analysis." Adv Ther. 2025;42(1):10-35. doi:10.1007/s12325-024-03019-0
11. Siegel S, et al. "Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation." J Urol. 2018;199(1):229-236. doi:10.1016/j.juro.2017.07.010
12. Heesakkers JPFA, et al. "Two-Year Efficacy and Safety Outcomes of the Pivotal OASIS Study Using the Revi System for Treatment of Urgency Urinary Incontinence." J Urol. 2025;213(3):323-332. doi:10.1097/JU.0000000000004328
13. Wang M, et al. "Percutaneous tibial nerve stimulation for overactive bladder syndrome: a systematic review and meta-analysis." Int Urogynecol J. 2020;31(12):2457-2471. doi:10.1007/s00192-020-04429-8
14. Valencia Technologies. "eCoin Peripheral Neurostimulator Physician Manual, Model UUI." FDA PMA P200036D, Document 903-1225 Revision PB, p.12. FDA labeling
15. Sumitomo Pharma America, Inc. GEMTESA (vibegron) tablets, for oral use: US Prescribing Information. Revised February 2025. Label.
16. European Association of Urology. EAU Guidelines on Non-neurogenic Female LUTS: Disease Management. 2026. Guideline.